ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 776

Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma

Christina Schutt1, Emily Mirizio 2, Claudia Salgado 3, Miguel Reyes-Mugica 3, Kaila L. Schollaert 2 and Kathryn Torok 3, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, 3UPMC Children's Hospital of Pittsburgh, Pittsburgh

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Juvenile scleroderma, morphea and histology, Pediatric rheumatology, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Localized scleroderma (LS) is a progressive autoimmune disease of the skin and underlying tissue that is characterized by an initial inflammatory infiltration which is followed by fibrosis and collagen deposition.  When left unchecked LS causes significant functional disability and disfigurement, especially in developing children.  Histopathologic review of LS skin biopsies typically shows a stronger inflammatory or fibrotic pattern depending on disease stage.  Our goal was to determine the transcriptome within inflammatory vs. fibrotic tissue to identify potential molecular targets using RNA sequencing (RNAseq) compared to histology scoring of inflammatory infiltrates vs. collagen deposition/fibrosis.  Differentially expressed genes (DEGs) in LS patients were compared to skin histopathological features to determine correlation.

Methods: RNAseq was performed on paraffin-embedded skin (n=15 LS, n=2 pediatric healthy) using the Illumina HTS and TrueSeq Access library preparation.  Paired-end RNAseq data was aligned using STAR and analyzed for DEGs using DESeq2.  Genes were analyzed using DEG cutoffs of log fold change > ±2.0, adjusted p< 0.05, and a false discovery rate (FDR) cutoff of < 0.05 for Ingenuity Pathway Analysis (IPA) and enrichment software (GSEA©).  Skin biopsies were reviewed by 2 blinded pathologists who determined 3 areas of inflammatory infiltrate per skin layer (papillary dermis, upper and lower reticular dermis) and counted total inflammatory cells (lymphocytes and plasma cells) per infiltrate, which determined a categorical inflammation score.  Similar scoring was also developed for fibrosis, where 3 areas were chosen per skin layer and 3 measurements of collagen bundle thickness were taken.  The average of these measurements was used for fibrotic scoring.  Spearman’s correlation between genes of interest and histology scoring was performed using GraphPad Prism. Results: The degree of inflammatory cell infiltrate significantly correlated with both inflammatory (IFNγ, immunoglobulin, and T-cell activation, rs > ±0.5, p< 0.01) and fibrotic (IL-12 mediated signaling, and DNA damage response) (rs > ±0.5, p< 0.05) genes (Table 1).  Collagen thickness did not correlate with typical fibrotic genes, but did correlate (rs > ±0.4, p< 0.05) with upregulated inflammatory genes, such as those associated with interferon signaling and T-cell activation (Table 1).  Further support of IFN-related signaling, T lymphocyte activation, and cytokine production was demonstrated with IPA. Conclusion: The identified immune pathways and genes corresponding with the LS skin inflammatory infiltrate indicate a unique genetic signature present during active disease with moderate-severe lymphoplasmacytic infiltrate and collagen thickness.  This may indicate that fibrosis occurring in later stages of LS is an inflammation-driven process.  Further investigation into the relationship and functions of these genes is underway and will aid in advancing treatment options for LS patients.


Table 1 Correlation Analysis Between Histology Features and Differentially Expressed Genes FINAL


Disclosure: C. Schutt, None; E. Mirizio, None; C. Salgado, None; M. Reyes-Mugica, None; K. Schollaert, None; K. Torok, None.

To cite this abstract in AMA style:

Schutt C, Mirizio E, Salgado C, Reyes-Mugica M, Schollaert K, Torok K. Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/genetic-signatures-support-inflammation-driven-fibrosis-in-localized-scleroderma/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-signatures-support-inflammation-driven-fibrosis-in-localized-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology